Yungjin Pharm. Co., Ltd.

KSE 003520.KS

Yungjin Pharm. Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2023: -4.32%

Yungjin Pharm. Co., Ltd. Return on Equity (ROE) is -4.32% for the year ending December 31, 2023, a 82.31% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Yungjin Pharm. Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2022 was -24.44%, a -121.28% change year over year.
Yungjin Pharm. Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2021 was -11.04%, a -9,392.59% change year over year.
Yungjin Pharm. Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2020 was -0.12%, a -102.68% change year over year.
Yungjin Pharm. Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2019 was 4.35%, a 179.49% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

KSE: 003520.KS

Yungjin Pharm. Co., Ltd.

CEO	Mr. Chae-Joon Lee
IPO Date	Jan. 8, 2001
Location	South Korea
Headquarters	13, Olympic-ro 35da-gil
Employees	574
Sector	Healthcare
Industries Pharmaceuticals Cleaning Supplies Drugstores & Retail Pharmacies Non-Alcoholic Beverages Personal Care Pet Food Plastics Soft Drinks & Sodas

Description

Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea. It provides cephalosporin antibiotic, antipsychotic, cardiovascular, and nutrition products. The company was founded in 1952 and is headquartered in Seoul, South Korea. Yungjin Pharm. Co., Ltd. is a subsidiary of KT&G Corporation.

Key trends

Past 5 years